RUNX1 and leukemia: However, targeted repression of EVI1 based on small molecule, epigenetic, and metabolic approaches impairs leukemia progression in preclinical cancer models, suggesting that EVI1 represents a cancer dependency and a tumor biomarker for high-risk AML15–17.